Tumor News and Research

RSS

Cancer cell targeting using multiple aptamers conjugated on nanorods

Aptamers, short stretches of DNA or RNA that can act much like antibodies, have shown promise as targeting agents for selective nanoparticle trafficking to tumors.

16 Jan 2008

Polymeric nanoparticles for tumor vaccines

The quest for an effective antitumor vaccine has received a boost from the results of work aimed at developing a nanoparticle that delivers tumor antigens to the immune system cells that trigger antibody production.

16 Jan 2008

Unique role of apoptosis protein TRADD in viral signaling

Epstein-Barr virus is incredibly common in humans; up to 95% of adults in the developed world have been infected, which causes glandular fever and has been linked to the development of several forms of cancer.

16 Jan 2008

The link between combined HRT use and the risk of lobular breast cancers

Postmenopausal women who take combined estrogen/progestin hormone-replacement therapy for three years or more face a fourfold increased risk of developing various forms of lobular breast cancer, according to new findings by researchers at Fred Hutchinson Cancer Research Center.

15 Jan 2008

Stem cells make bone marrow cancer resistant to treatment

Scientists at the Johns Hopkins Kimmel Cancer Center say they have evidence that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatments.

15 Jan 2008

U.S. Food and Drug Administration approves new genetic breast cancer test

The U.S. Food and Drug Administration has approved a test that helps in assessing the risk of tumor recurrence and long-term survival for patients with relatively high-risk breast cancer. The TOP2A FISH pharmDx is the first approved device to test for the TOP2A (topoisomerase 2 alpha) gene in cancer patients.

14 Jan 2008

Etanercept drug reverses early symptoms of Alzheimer's in 10 minutes

Scientists in the U.S. say a drug which can reverse some of the early symptoms of Alzheimer's disease takes effect within 10 minutes.

14 Jan 2008

Lymphangioleiomyomatosis - potential clues into the treatment and diagnosis

Studies published in the Jan. 10 edition of the New England Journal of Medicine (NEJM) are providing clues into the treatment and diagnosis of LAM, or lymphangioleiomyomatosis, a progressive and deadly lung disease that affects women in their childbearing years.

11 Jan 2008

Scientists identify cells that promote formation of lethal lung metastases

Cancer patients usually ask what can be done after a primary tumor has already spread, or metastasized, to other organs.

11 Jan 2008

Body's immune system uses common molecule to recognize prostate tumors

In experiments with mice, researchers have found that the body's immune system can use a surprisingly common molecule to recognize prostate tumors.

11 Jan 2008

Investigational treatment for advanced melanoma to be studied

University of Illinois at Chicago researchers are participating in a multi-center research trial to evaluate the safety and effectiveness of Allovectin-7, an investigational treatment for advanced melanoma.

10 Jan 2008

The drug sirolimus shrinks tumors, improves lung function

The drug sirolimus, normally used to help transplant patients fight organ rejection, may eventually be used as a less invasive treatment for a tumor called angiomyolipomata in patients with who would otherwise face surgery.

10 Jan 2008

Small pieces of ribonucleic acid prevent spread of breast cancer

Howard Hughes Medical Institute researchers have identified small pieces of ribonucleic acid (RNA) that suppress the spread of breast cancer to the lungs and bone.

10 Jan 2008

RNA silences cancer suppressor gene

One way cancer arises is when tumor suppressor genes that normally keep cell growth in check are mysteriously turned off.

10 Jan 2008

New study highlights importance soluble proteins, called cytokines, in Alzheimer's

An extraordinary new scientific study, which for the first time documents marked improvement in Alzheimer's disease within minutes of administration of a therapeutic molecule, has just been published in the Journal of Neuroinflammation .

10 Jan 2008

Morphotek announces agreement for development of antibodies to treat prostate cancer

Morphotek, Inc., a subsidiary of Eisai Co., Ltd., has announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers.

10 Jan 2008